We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key Metrics
Read MoreHide Full Article
For the quarter ended March 2023, Jazz Pharmaceuticals (JAZZ - Free Report) reported revenue of $892.81 million, up 9.7% over the same period last year. EPS came in at $3.95, compared to $3.73 in the year-ago quarter.
The reported revenue represents a surprise of -0.59% over the Zacks Consensus Estimate of $898.11 million. With the consensus EPS estimate being $4.26, the EPS surprise was -7.28%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Product sales, net: $884.22 million versus $890.37 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
Revenues- Royalties and contract revenues: $8.59 million versus the nine-analyst average estimate of $7.74 million. The reported number represents a year-over-year change of +121.2%.
Total revenues- Oncology- Defitelio(defibrotide)/defibrotide: $39.08 million versus the eight-analyst average estimate of $50.38 million. The reported number represents a year-over-year change of -21%.
Total revenues- Oncology- Vyxeos: $36.70 million versus the eight-analyst average estimate of $33.84 million. The reported number represents a year-over-year change of +8.7%.
Total revenues- Oncology- Zepzelca (lurbinectedin): $67.18 million compared to the $74.48 million average estimate based on eight analysts. The reported number represents a change of +13.2% year over year.
Total revenues- Other: $3.43 million compared to the $1.06 million average estimate based on eight analysts. The reported number represents a change of +264.2% year over year.
Total revenues- Neuroscience- Epidiolex/Epidyolex: $188.91 million versus $193.03 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +19.6% change.
Total revenues- Oxybate- Xyrem: $178.13 million compared to the $185.19 million average estimate based on seven analysts. The reported number represents a change of -28% year over year.
Total revenues- Neuroscience- Sativex: $7.10 million versus the seven-analyst average estimate of $4.36 million. The reported number represents a year-over-year change of +49.7%.
Total revenues- Oncology- Rylaze: $85.93 million compared to the $74.14 million average estimate based on seven analysts.
Total revenues- Oxybate- Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: $277.76 million versus the seven-analyst average estimate of $269.85 million. The reported number represents a year-over-year change of +49.3%.
Total revenues- Total Oxybate: $455.89 million compared to the $453.72 million average estimate based on six analysts. The reported number represents a change of +5.2% year over year.
Shares of Jazz have returned -7.7% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key Metrics
For the quarter ended March 2023, Jazz Pharmaceuticals (JAZZ - Free Report) reported revenue of $892.81 million, up 9.7% over the same period last year. EPS came in at $3.95, compared to $3.73 in the year-ago quarter.
The reported revenue represents a surprise of -0.59% over the Zacks Consensus Estimate of $898.11 million. With the consensus EPS estimate being $4.26, the EPS surprise was -7.28%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $884.22 million versus $890.37 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
- Revenues- Royalties and contract revenues: $8.59 million versus the nine-analyst average estimate of $7.74 million. The reported number represents a year-over-year change of +121.2%.
- Total revenues- Oncology- Defitelio(defibrotide)/defibrotide: $39.08 million versus the eight-analyst average estimate of $50.38 million. The reported number represents a year-over-year change of -21%.
- Total revenues- Oncology- Vyxeos: $36.70 million versus the eight-analyst average estimate of $33.84 million. The reported number represents a year-over-year change of +8.7%.
- Total revenues- Oncology- Zepzelca (lurbinectedin): $67.18 million compared to the $74.48 million average estimate based on eight analysts. The reported number represents a change of +13.2% year over year.
- Total revenues- Other: $3.43 million compared to the $1.06 million average estimate based on eight analysts. The reported number represents a change of +264.2% year over year.
- Total revenues- Neuroscience- Epidiolex/Epidyolex: $188.91 million versus $193.03 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +19.6% change.
- Total revenues- Oxybate- Xyrem: $178.13 million compared to the $185.19 million average estimate based on seven analysts. The reported number represents a change of -28% year over year.
- Total revenues- Neuroscience- Sativex: $7.10 million versus the seven-analyst average estimate of $4.36 million. The reported number represents a year-over-year change of +49.7%.
- Total revenues- Oncology- Rylaze: $85.93 million compared to the $74.14 million average estimate based on seven analysts.
- Total revenues- Oxybate- Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: $277.76 million versus the seven-analyst average estimate of $269.85 million. The reported number represents a year-over-year change of +49.3%.
- Total revenues- Total Oxybate: $455.89 million compared to the $453.72 million average estimate based on six analysts. The reported number represents a change of +5.2% year over year.
View all Key Company Metrics for Jazz here>>>Shares of Jazz have returned -7.7% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.